Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway

Bhuvaneswari Ramaswamy1,5, Yuanzhi Lu2, Kun-yu Teng2, Gerard Nuovo3, Xiaobai Li4, Charles L. Shapiro1,5, and Sarmila Majumder2,5

Abstract

Endocrine resistance is a major challenge in the management of estrogen receptor (ER)-positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of patients developing resistance to endocrine therapy warrants additional studies. Here we show that noncanonical Hedgehog (Hh) signaling is an alternative growth promoting mechanism that is activated in tamoxifen-resistant tumors. Importantly, phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role in regulating Hh signaling by protecting key components of this pathway from proteosomal degradation. The levels of Hh-signaling molecules SMO and GLI1 and the targets were significantly elevated in tamoxifen-resistant MCF-7 cells and T47D cells. Serial passage of the resistant cells in mice resulted in aggressive tumors that metastasized to distant organs with concurrent increases in Hh marker expression and epithelial mesenchymal transition. RNAi-mediated depletion of SMO or GLI1 in the resistant cells resulted in reduced proliferation, clonogenic survival and delayed G1–S transition. Notably, treatment of resistant cells with PI3K inhibitors decreased SMO and GLI1 protein levels and activity that was rescued upon blocking GSK3β and proteosomal degradation. Furthermore, treatment of tamoxifen-resistant xenografts with anti-Hh compound GDC-0449 blocked tumor growth in mice. Importantly, high GLI1 expression correlated inversely with disease-free and overall survival in a cohort of 315 patients with breast cancer. In summary, our results describe a signaling event linking PI3K/AKT pathway with Hh signaling that promotes tamoxifen resistance. Targeting Hh pathway alone or in combination with PI3K/AKT pathway could therefore be a novel therapeutic option in treating endocrine-resistant breast cancer. Cancer Res; 72(19); 5048–59. ©2012 AACR.

Introduction

Breast cancer is the most common cause of cancer-related death in women globally. Death rates from breast cancer have been steadily decreasing since 1990, which is attributed largely to better screening methods and improved treatment options. Perhaps, the major breakthrough in the treatment of breast cancer was the development of targeted therapies with drugs such as tamoxifen, a selective estrogen receptor (ER) modulator that blocks estrogen signaling. This therapeutic approach has been successfully used to treat approximately two-thirds of ER-positive breast cancers resulting in 50% improvement in disease-free survival (1). A recurring problem is, however, the development of acquired resistance to ER-targeted therapies in about 30% to 40% of the woman treated with tamoxifen for 5 years. Several signaling pathways are implicated in tamoxifen resistance including PI3K/mTOR/Akt, HER2/ERB, and insulin-like growth factor receptor (IGF-R) pathways (2–6). A few agents targeting these pathways in hormone-refractory breast cancers are in clinical trials (5, 7). To date, however, there is no approved targeted therapy to improve outcomes in hormone-refractory breast cancers without resorting to chemotherapy.

The hedgehog (Hh) signaling pathway is highly conserved and plays a crucial role in vertebrate embryogenesis (8). The Hh ligands (SHH, IHH, and DHH) bind to the cell surface receptor Patched (PTCH), which otherwise inhibits the activity of the transmembrane receptor like protein Smoothened (SMO). Release of SMO from PTCH-mediated repression results in posttranslational processing of the GLI (glioma-associated oncogene homolog)–zinc-finger transcription factors. Three mammalian GLI proteins are known to exist out of which GLI1 and GLI2 usually act as transcriptional activators and GLI3 acts as a transcriptional repressor (9). Aberrant activation of the Hh pathway has been reported in several cancers including basal cell carcinomas, medulloblastomas,
pancreatic adenocarcinomas, and glioblastomas (10–12). Several lines of evidence point toward involvement of Hh signaling in breast carcinogenesis, and hence provide an attractive, rational therapeutic target in treating this cancer (13).

Mice with heterozygous disruption of Ptch1 showed marked abnormalities in mammary glands resembling ductal dysplasias and hyperplasias (14). Further, expression of activated human SMO (SmooM2) in mouse mammary epithelium led to increased proliferation, altered differentiation, and ductal dysplasias distinct from those caused by Ptch1 heterozygosity (15). Hh signaling is also activated in human mammary stem/progenitor cells and is downregulated upon cell differentiation (16). It may also play a part in breast cancer progression through its role in communication between epithelial and stromal compartments (17, 18). Furthermore, higher expression of SHH in breast tumors was significantly associated with increased risk of metastasis and breast cancer-specific death (19).

Here we present in vitro and in vivo data showing the dependence of endocrine-resistant breast cancer cells on activated Hh signaling for growth and the mechanism for this activation. In addition, we also present data supporting the clinical use of Hh inhibitors in endocrine-resistant tumors.

Materials and Methods

Reagents

Inhibitors of PI3K (LY294002 and Wortmannin) and glyco- gen synthase kinase-3 (GSK-3; LiCl) were from Sigma. AKT inhibitor [1-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate] was from EMD Biosciences. GDC-0449 was synthesized at the Pharmacology core facility of The Ohio State University, following published protocol (20). MISON siRNA universal negative Control and siRNA to SMO and GLI1 were from Sigma.

Cell culture and tissue procurement

Tamoxifen-sensitive MCF7 cells and OHTR100 cells (resistant to 100 nmol/L tamoxifen) were obtained from Dr. Kenneth P. Nephew (Indiana University, Bloomington, Indiana) and maintained as described (21). OHTR100 cells were further cultured in 500 nmol/L 4-hydroxy tamoxifen (4-OHT) for 1 month to obtain the OHTR500 cells, followed by exposure to 1,000 nmol/L tamoxifen to obtain the OHTR1000 cells. T47D cells were obtained from American Type Culture Collection and maintained as instructed. Cell lines were not passaged longer than 6 months after receipt. Primary human breast samples were obtained from the Stephanie Spielman Tissue Bank (protocol 2003C0036).

RT-PCR analysis

cDNA was synthesized from DNase-treated total RNA and gene expression (SHH, SMO, GLI1, GLI2, and GLI3) was measured in quadruplicate using Taqman assays (Applied Biosys- tems). Expression of SNAIL, MYC, and BMI1 was measured using Sybr Green chemistry.

Western blot analysis

Whole cell extracts were prepared in the cell lysis buffer, followed by immunoblotting as described (22). Protein expres- sion was quantified by the ImageJ Software (http://rsbweb.nih.gov/ij/).

Plasmids, transfections, and luciferase assay

Dr. Hiroshi Sasaki gifted a 8×3′Gli BS-5′-Luc plasmid (9). pLKO.1–shGLI1 plasmid was from Thermo Scientific. Cells (1.6×10^7/well) seeded in a 24-well plate were transfected for 6 hours with 8×3′Gli BS-5′-Luc plasmid and pRLTK (internal control, Promega) using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured using the Dual-Luciferase Assay System (Promega) after 48 hours of transfection. OHTR2nd cells were routinely used to study the mechanism of Hh pathway activation as this pathway is highly active in these cells.

Cell proliferation assay

Cells (4,000/well) seeded in 96-well plates were serum starved overnight and treated with 5 μmol/L tamoxifen for 72 hours. Cell proliferation was monitored using a MTT assay kit (Roche Molecular Biochemicals), following company’s protocol.

Colonies formation assay

The assay was conducted as described previously (23). Briefly, exponentially growing cells (500/well) in 6-well plates were treated with indicated concentrations of tamoxifen for 2 weeks. When colonies were readily visible (>50 cells/colony) they were fixed in methanol and stained with 1% crystal violet solution. The colony number was quantified using the AlphaView Software 3.1 (FluorChem Q).

Flow cytometric analysis

Trypsinized cells were fixed in ice-cold 70% ethanol and stored at −20°C. Before analysis, samples were washed in phosphate-buffered saline (PBS) and stained with 5.0 μg/mL propidium iodide in PBS containing 0.2 mg/mL RNaseA. The single-cell suspensions were analyzed by a FACScalibur (BD Biosciences) using the Cell Quest Software, and cell-cycle distribution was assessed using the ModFit program (Verity Software House).

Mouse mammary tumor induction and drug treatment

Cells (5×10^4) were grafted in mammary fat pads of ovari- eetomized Balb/c nude mice (Charles River Laboratory) with subcutaneous (s.c) supplementation of 0.72 mg 17β-estradiol pellet (Innovative Research of America). When the tumor reached approximately 100 mm^3, the mice received 5 mg, 60- day sustained release pellet of tamoxifen citrate (Innovative Research of America) subcutaneously. Freshly formulated suspension of GDC-0449, in 0.5% methylcellulose, 0.1% Tween-80 (24) was administered orally at 100 μg/kg body weight (25), twice daily for 10 days. Length (L) and width (W) of the tumors were measured twice a week, and tumor volume was calculated using the formula \( \pi L^2W \)/6, as previously described (26). At least 5 animals per group were used in each experiment.

Immunohistochemical analysis

The expression of Hh markers in primary tumors was determined by immunohistochemistry using Benchmark LT
automated system (Ventana Medical Systems; ref. 27). The positive and negative controls are expressing and non-expressing tissues, respectively, with and without primary antibody. Expressions of the markers were scored on the basis of percentage-positive cells and intensity of the staining by two independent pathologists. In case of discrepancy, an independent reader was consulted and consensus was obtained. A score of 10% or more was considered positive. All clinical follow-up was derived from the James Tumor Registry, OSU with a median follow-up of 96 months (0.93, 139.1 months).

Statistical analysis
The standard 2-tailed Student t-test was used for 2 data sets. ANOVA followed by Bonferroni/Dunn posttests were used for data sets with multiple groups using Prism 5.0 (GraphPad Software Inc). Two-sided P values of equal or less than 0.05 were deemed to be statistically significant. Representative data from 2 to 3 reproducible experiments are presented, where error bars represent standard deviation (SD) or standard error of the mean (SEM) in animal experiments. For patient data, summary statistics were calculated to show patient characteristics. Fisher’s exact test was used to evaluate the association between 2 categorical variables, such as 2 Hh markers expression levels (high vs. low for both). Staining score of 10% or more was considered high as mentioned in the methodology section.

Survival analysis was conducted to assess the impact of Hh marker expression and other known clinical prognostic factors (age at diagnosis, tumor grade, breast cancer subtypes, and nodal status) on disease-free and overall survival. Survival curves were estimated by Kaplan–Meier plots for a dichotomized variable and compared by the log-rank test. Variables with a P value less than 0.05 in the univariate Cox regression analysis were further examined in multivariate Cox regression models. Proportional hazard assumption was checked during the modeling process. Upon significant violation of the assumption, stratified Cox models were utilized by including the predictor as a stratification factor. The covariate adjusted hazard ratio (HR) and the 95% confidence interval (CI) for the Hh marker of interest was reported on the basis of the modeling process. Upon significance of the univariate Cox model, the predictor was entered into a multiple Cox model. The log-rank test was used to test the predictor as a stratification factor of increased expression of genes encoding Hh pathway components and their protein levels were analyzed in tamoxifen-sensitive and tamoxifen-resistant breast cancer cell lines. The model cell lines used for this study were tamoxifen-sensitive MCF7 cells and a panel of MCF7 cells that are resistant to increasing concentration of tamoxifen (Supplementary Fig. 5IB), showing the resistance. Real-time RT-PCR revealed a consistent increase in expression of SMO, SMO, and GLI1 in the OHTR cell panel that correlated with the level of tamoxifen resistance (Fig 1A), whereas GLI2 and GLI3 expression were not significantly changed (data not shown). There was no marked change in the amount of PTCH RNA in OHTR cells (Fig. 1A). Western analysis of the Hh signaling molecules confirmed a marked increase in the protein levels of SMO and GLI1 in the resistant cells, whereas SHH was not detected (Fig. 1B). The protein levels of PTCH (Fig. 1B), GLI2, and GLI3 remain unaltered (Supplementary Fig. SIC).

It is known that T47D cells are relatively more resistant to tamoxifen compared with other ER-positive cell lines (28). Consistent with this finding, the level of SMO and GLI1 proteins were significantly higher in the T47D cells compared with tamoxifen-sensitive cell lines MCF7 and BT474 (Fig.1C). In contrast, the expression of PTCH was comparable in all cell lines.

Because GLI1 is a transcription factor, we tested the functional significance of increased expression of this gene in the tamoxifen-sensitive and tamoxifen-resistant cells, using a GLI responsive luciferase reporter vector (9). Analysis of luciferase expression revealed a 6- to 7-fold increase in promoter activity in the OHTR cells compared with the MCF7 cells (P < 0.001; Fig. 1D), showing that transcriptional activity of GLI1 is comparatively higher in the tamoxifen-resistant cells. Furthermore, depletion of GLI1 using GLI1-specific shRNA led to about 65% (P < 0.01) decrease in GLI-driven promoter activity (Fig. 1E).

We next analyzed the expression of the Hh target genes in the MCF-7 and OHTR cell lines. The expression of SNAIL, Bmi1, and MYC mRNA in tamoxifen-resistant cells were significantly increased (2.5- to 4-fold; Fig. 1F). MYC and Bmi1 protein levels were also found to be markedly higher (~5-fold and >17-fold, respectively) in the tamoxifen-resistant cells, and directly correlated with higher levels of tamoxifen resistance (Fig. 1G).

Tamoxifen-resistant xenografts in mouse mammary gland undergo micro-metastasis with concurrent increase in Hedgehog signaling
To study further the relationship between activated Hh signaling and tamoxifen resistance of breast tumors in vivo, tumor xenografts were established in Balb/c nude mice using OHTR100 cells. The tumors were serially passaged in mice treated with tamoxifen and a consistent increase in the growth rate of the tumors was observed after each passage (Fig. 2A). Microscopic analysis of hematoxylin and eosin stain (H&E) sections from the liver and lung of mice after the third passage revealed metastatic lesions in both tissues, indicating that the tamoxifen-resistant cells acquired a more aggressive phenotype after in vivo passage (Fig. 2B). After each in vivo passage, cells were isolated from the macro-dissected tumors and cultured in vitro (OHTR1st, 2nd, and 3rd). Comparison of the morphology of these cells revealed the acquisition of a more mesenchymal phenotype in the OHTR3rd cells (Fig. 2C). Consistent with this finding, we observed increased expression of vimentin, decreased expression of E-cadherin (Fig. 2D) and increased mammosphere formation (Supplementary Fig. S2A).
and B) in \textit{in vivo} passaged cells. The expression of SMO and GLI1 increased after successive passages and were significantly higher (~3-fold) in the cells derived after the second and third passage in the mice (Fig. 2E). Similar increases in expression of the GLI1 target genes MYC were also observed (Fig. 2E). Immunocytochemical analysis revealed a marked increase in SMO, GLI1, and BMI1 in tamoxifen-resistant cells, with distinct nuclear localization of GLI1 (Fig. 2F). These data showed a strong relationship between acquisition of the aggressive phenotype of tamoxifen-resistant cells \textit{in vivo} and the activation of Hh signaling in the resistant tumors.

**Knockdown of Hh pathway components inhibits growth of tamoxifen-resistant cells**

To determine the functional significance of Hh pathway in tamoxifen resistance, we depleted SMO and GLI1 from OHTR2\textsuperscript{nd} cells using the respective siRNA pools (Fig. 3A). A 60% decrease in SMO and 30% decrease in GLI1 protein level was routinely observed in the siRNA-transfected cells (Fig 3A). Comparison of cell proliferation to the scrambled siRNA-transfected control cells revealed a 66% ($P < 0.001$) and 25% ($P < 0.001$) decrease in growth of SMO- and GLI1-depleted cells, respectively. In the presence of 1.0 \(\mu\)mol/L tamoxifen, the
growth of SMO-depleted cells was further reduced by 25% \((P < 0.001)\) and that of GLI1-depleted cells by an additional 12% \((P < 0.05)\), whereas the growth of the control cells remained unaffected (Fig. 3B). When assessed for clonogenic growth, we observed a 30% \((P < 0.001)\) decrease in colony formation upon depletion of both SMO and GLI1. In the presence of 1.0 and 2.0 \(\mu\)mol/L tamoxifen, the colony formation was reduced by approximately 50% \((P < 0.001)\) and 85% \((P < 0.01)\), respectively, when SMO or GLI1 was depleted compared with the tamoxifen-treated control cells (Fig. 3C). Cell cycle analysis revealed significant retention of GLI1-depleted cells in the G1 phase both in the absence \((P < 0.001)\) and presence of tamoxifen \((P < 0.001)\) at 6 and 12 hours compared with the control cells (Fig. 3D). There was no increase in the sub-G0 population or apoptosis (Supplementary Fig. S3A and B). Similar growth suppression and sensitization to tamoxifen were also observed in 2 independently derived GLI1 shRNA knockdown T47D clones (Supplementary Fig. S3C–E). These clones showed decreased growth in the presence of tamoxifen and, decreased colony formation.

Analysis of target gene expression in SMO-depleted OHTR2nd cells and GLI1-depleted T47D cells revealed a marked reduction in the MYC protein \((45\%, \text{Fig. 3E})\) and RNA level in both the cell lines \((\text{OHTR}: 60\%, \text{T47D}: 63\text{–75}\%, \text{Fig. 3E and Supplementary Fig. S3F})\). Further, the expression of BMI1 and SNAIL were also significantly reduced in these cells \((<50\%\) and \(>75\%\), respectively, Fig. 3E, Supplementary Fig. S3F) and GLI1-depleted OHTR cells (data not shown).

### The PI3K/AKT pathway activates Hh signaling in tamoxifen-resistant breast cancer

To elucidate the mechanism underlying aberrant activation of Hh pathway in tamoxifen-resistant breast cancer, we first used the GLI-luciferase reporter to determine whether a SHH autocrine loop could account for pathway activation in resistant cell. While the GLI reporter was strongly activated in OHTR2nd cells, addition of recombinant SHH ligand had no effect on luciferase activity in OHTR2nd or MCF7 cells (Fig. 4A). The data suggested that a noncanonical pathway might function to activate Hh signaling components and contribute to
tamoxifen resistance of these cells. To test this hypothesis, OHTR2\textsuperscript{nd} cells were routinely used to study the mechanism of Hh pathway activation as this pathway is highly active in these cells.

We hypothesized that the PI3K/AKT pathway, known to be associated with poor patient outcome in endocrine-resistant breast tumors (29, 30) is involved in Hh pathway activation. Consistent with this hypothesis, treatment with 20 \textmu{}mol/L of LY294002, a specific inhibitor of PI3K, resulted in a 50% decrease in GLI-dependent luciferase activity in OHTR2\textsuperscript{nd} cells, but not in MCF7 cells (Fig. 4B). Similar inhibition of the GLI-reporter was also observed when cells were treated with 500 nmol/L of Wortmanin (45%, \(P < 0.05\)) or 20 \textmu{}mol/L of a specific AKT inhibitor [1L-6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecylcarbonate; 46%, \(P < 0.05\); Supplementary Fig. S4A]. The inhibition by LY294002 was rescued when the constitutively active PI3K subunit P110 or an activated form of AKT was ectopically expressed in these cells (Fig. 4C–D).

Figure 3. SMO and GLI1 depletion inhibits tamoxifen-resistant cell growth. A, Western analysis of SMO and GLI1 knocked down OHTR2\textsuperscript{nd} cells quantified in the bar diagram. B and C, cell proliferation assay (B) and clonogenic survival of SMO and GLI1 depleted cells in the absence (T0) and presence of 2 \textmu{}mol/L tamoxifen (T2) quantified in the bar diagram (C). D, cell-cycle analysis of GLI1-depleted OHTR2\textsuperscript{nd} cells without (T0) and with (T5) 5 \textmu{}mol/L tamoxifen treatment. E and F, Western analysis of MYC (E) and real-time RT-PCR of MYC, SNAIL, and BMI1 (F) in SMO-depleted OHTR2\textsuperscript{nd} cells.
Furthermore, when vectors expressing dominant negative versions of P110 or AKT were transfected in the OHTR2nd cells, the luciferase activity decreased by more than 90% and 25%, respectively (Fig. 4E). Conversely, coexpression of a constitutively active form of P110 in MCF7 cells resulted in nearly 2-fold (P < 0.01) increase in GLI-reporter activity. Figure 4. PI3K/AKT pathway activates Hh signaling in tamoxifen-resistant cells. A, GLI-driven luciferase activity in OHTR2nd and MCF-7 cells treated with SHH. B, luciferase activity in OHTR2nd and MCF-7 cells treated with DMSO (Con) and 20 μmol/L LY294002 for 3 hours. C and D, luciferase activity in OHTR2nd cells overexpressing constitutively active P110 subunit of PI3K (P110+C), and constitutively active AKT (AKT+) or the corresponding empty vectors (C). E and F, luciferase activity in OHTR2nd cells overexpressing dominant negative mutants of PI3K [P110(KR)] or AKT [AKT(KR)]. E and in MCF-7 cells overexpressing P110+ or AKT+ (F). Ectopic expression of P110 and AKT mutants are shown in the inset. Western analysis of SMO and GLI1 in OHTR2nd cells treated with 20 μmol/L LY294002 (LY), 50 mmol/L LiCl for 6 hours alone or in combination of 50 μmol/L MG132 (H), and of SMO in OHTR2nd cells treated with 20 μmol/L LY294002 (LY) and/or 50 mmol/L LiCl for 6 hours, or 50 μmol/L MG132 for the last 1 hour (I), as indicated. Bar diagrams present quantified data.
A small but significant increase in reporter activity was also observed in MCF-7 cells forced to express constitutively active AKT (0.25-fold, \( P = 0.045 \); Fig. 4F).

To explore a potential mechanism underlying the PI3K pathway-activated Hh signaling, SMO and GLI1 protein levels were measured in LY294002-treated OHTR2nd cells. These cells showed approximately 50% decrease in SMO protein levels compared with vehicle dimethyl sulfoxide (DMSO)-treated controls (Fig. 4G, left). A similar reduction in GLI1 level was also observed after treatment with LY294002 (Fig. 4G, right).

GSK3\( \beta \) is a serine-threonine kinase that is negatively regulated by PI3K/AKT-mediated phosphorylation. We hypothesized that GSK3\( \beta \)-mediated phosphorylation of SMO and GLI1 facilitate ubiquitination and subsequent proteasomal degradation of these proteins in breast tumor cells. Activation of AKT in tamoxifen-resistant cells could thus rescue proteasomal degradation of these proteins by inhibiting GSK3\( \beta \). Indeed, bioinformatics analysis using GPS software (31) revealed the presence of several potential phosphorylation motifs in SMO (Supplementary Table S1) and in GLI1 (Supplementary Table S2). To test this hypothesis, OHTR2nd cells were treated with LiCl, a potent and specific inhibitor of GSK3\( \beta \), alone or with MG132 that inhibits proteasomal degradation. Western blot analysis showed approximately a 2-fold increase in SMO and GLI1 protein in the presence of LiCl or MG132 alone or in combination (Fig. 4H). Furthermore, stabilization of SMO and GLI1 by LiCl and MG132 was blocked when the cells were treated simultaneously with the PI3K inhibitor (Fig. 4I and Supplementary Fig. S4B).

These data showed that GSK3\( \beta \)-mediated phosphorylation can indeed lead to proteasomal degradation of these two proteins and that the PI3K/AKT pathway plays a key role in stabilizing these signaling molecules thereby promoting activation of the Hh pathway in the resistant cells.

GDC-0449, a small molecule inhibitor of SMO inhibits tamoxifen-resistant cell growth both in vitro and in vivo

GDC-0449, a small molecule inhibitor of SMO is in clinical trials for several cancers with activated Hh pathway (http://clinicaltrials.gov), including one in breast cancer. We used this compound to determine if the growth of tamoxifen-resistant cells could be suppressed with this inhibitor alone or in combination with tamoxifen using both in vivo and in vitro assays (Fig. 5A–D). For in vivo assays, xenografts were established in athymic nude mice with OHTR2nd cells. After implanted tumors reached approximately 100 mm\(^3\) in size, the mice were randomized in 4 groups: vehicle, tamoxifen alone, GDC-0449 alone, and both tamoxifen and GDC-0449. The mice were treated for 10 consecutive days and the tumor growth was monitored for an additional 2 weeks (Fig. 5A). While the control group tumor reached 500 mm\(^3\) in volume at the endpoint of the assay, the GDC-0449-treated tumors failed to grow. In fact, the tumors shrank by approximately 50% from the day of treatment by day 24. Treatment with tamoxifen...
alone caused a 2.5-fold reduction in tumor size compared with the control group, whereas the combination of both tamoxifen and GDC-0449 had no additional effect compared with GDC-0449 alone (Fig. 5B and C).

In in vitro studies, GDC-0449 alone inhibited the growth of OHTR2 and T47D cells by about 50% ($P < 0.05$). Importantly, the combination of GDC-0449 with tamoxifen suppressed growth of OHTR2 and T47D cells ($P < 0.001$, Fig. 5D and E) almost completely. Similar observations were also recorded with all other OHTR cell lines (data not shown). Growth of parental MCF7 cells was inhibited by approximately 15% when treated with GDC-0449 (data not shown). These data suggest that GDC-0449 alone could be a targeted therapy for patients with ER+ breast cancer who failed to respond to tamoxifen as the first line of therapy.

**GLI1 expression in primary human breast tumors correlates inversely with disease-free survival and overall survival**

To extend this key observation regarding the role of GLI1 in breast cancer to patient survival, tissue microarrays containing tissue cores representing 315 invasive breast cancers were stained for Hh markers. The tumors were obtained through a tissue banking protocol (OSU2009C009A) where patients with newly diagnosed breast cancer were consented to have their tumors stored for future research purposes and for long-term clinical follow-up. The median follow-up was 96 months. The clinicopathologic characteristics of the tumors are listed in Table 1. The expression of GLI1 and BMI1 are presented in Table 1. The expression of GLI1 and BMI1 are positively correlated with epithelial and stromal status ($P < 0.001$, Fig. 6A). Epithelial and stromal GLI1 expression was observed in 69% and 47% of the tumors, respectively. Epithelial GLI1 expression positively correlated with epithelial and stromal BMI1 expression ($P < 0.001$, Fig. 6A). A significant correlation was found between increased epithelial GLI1 expression and lymph node status ($P = 0.014$) but no significant association existed between GLI1 expression and ER ($P = 0.31$), PR ($P = 0.33$), HER2 ($P = 0.42$) status and grade ($P = 1$) of the tumor.

To establish a potential relationship between GLI1 overexpression and clinical outcomes, we first conducted univariate survival analysis. Univariate survival analysis showed that the following factors were associated with shorter disease-free survival: high-epithelial GLI1 expression, ER-negative status, lymph node-positive status, higher tumor grade, and Her2-positive tumors (Table 2). No significant association was found between GLI1 expression and age, race, and clinical outcomes in tamoxifen-resistant tumors. Acquired resistance to endocrine therapy such as tamoxifen is a major clinical concern in the management of patients with hormone-receptor-positive breast cancer, which is clearly a complex phenomenon involving multiple pathways (32–36). Receptor tyrosine-kinases have been frequently targeted to overcome endocrine resistance in the past. We have presented here compelling data using multiple approaches to show the role of Hh signaling

![Image](https://example.com/image.png)

**Table 1. Clinicopathologic features of primary breast tumors ($N = 315$)**

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>$N = 315$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Median 54.5 (Range 20–92)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>276 (88)</td>
</tr>
<tr>
<td>Black</td>
<td>35 (11)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Nodal status</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>179 (57)</td>
</tr>
<tr>
<td>Negative</td>
<td>110 (35)</td>
</tr>
<tr>
<td>Unknown</td>
<td>26 (8)</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>26 (8)</td>
</tr>
<tr>
<td>2</td>
<td>132 (42)</td>
</tr>
<tr>
<td>3</td>
<td>138 (44)</td>
</tr>
<tr>
<td>Unknown</td>
<td>19 (6)</td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>230 (73)</td>
</tr>
<tr>
<td>Negative</td>
<td>77 (24)</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 (3)</td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>206 (65)</td>
</tr>
<tr>
<td>Negative</td>
<td>99 (31)</td>
</tr>
<tr>
<td>Unknown</td>
<td>10 (3)</td>
</tr>
<tr>
<td>Her2 neu status</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>46 (15)</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>26 (8)</td>
</tr>
<tr>
<td>Negative</td>
<td>161 (51)</td>
</tr>
<tr>
<td>Unknown</td>
<td>82 (26)</td>
</tr>
</tbody>
</table>

Furthermore, we asked the question whether among patients that received tamoxifen as part of their adjuvant therapy, if high GLI1 expression resulted in worse DFS. Among the 98 patients with ER positive breast cancer, who received tamoxifen as part of their adjuvant therapy, there were only a total of 20 events in 10 years of follow-up and no statistically significant difference was seen between the groups with high or low expression of GLI1. Considering the overall excellent prognosis in this subset of patients, a larger sample size is needed to identify a statistically significant difference in clinical outcomes.

**Discussion**

We show here for the first time the efficacy of targeting Hh pathway using a small molecule SMO inhibitor in improving outcomes in tamoxifen-resistant tumors. Acquired resistance to endocrine therapy such as tamoxifen is a major clinical concern in the management of patients with hormone-receptor-positive breast cancer, which is clearly a complex phenomenon involving multiple pathways (32–36). Receptor tyrosine-kinases have been frequently targeted to overcome endocrine resistance in the past. We have presented here compelling data using multiple approaches to show the role of Hh signaling.
pathway in inducing tamoxifen-resistance, and the mechanism of its activation.

Furthermore, we have showed a significant correlation between activation of Hh signaling in primary tumors (n = 315), and disease outcomes, confirming the negative prognostic effect of high GLI1 expression on DFS and OS. Although GLI1 expression did not correlate with a particular molecular subtype, among ER positive, node positive tumors DFS was worse in tumors with high GLI1 expression. Hence the overall association of Hh activation and poor outcome in breast cancer signifies that activation of this pathway facilitates tumor growth and progression, supporting recently reported association of increased Hh ligand expression with increased risk of metastasis and breast cancer-specific death (19). Our in vivo study revealed that blocking SMO with GDC-0449 alone could effectively suppress the tamoxifen-resistant xenografts in mice. Unlike our in vitro studies, addition of tamoxifen to GDC-0449 had no further benefit, which could be because of the high dosage of GDC-0449 used in the in vivo studies, or the tamoxifen concentrations achieved in the tumor may be lower depending on its conversion to active metabolite in vivo. Using monoclonal antibody 5E1 to Hh ligand (Shh) O’Toole and colleagues showed metastases reduction in animal models of breast cancer (19). Our data is unique in showing that targeting the noncanonical Hh pathway specifically in ER-positive breast cancers that are tamoxifen resistant using a clinically available Hh inhibitor (GDC-0449) improves outcomes. GDC-0449 (vismodegib) is a well tolerated, orally bioavailable

Table 2. Univariate analysis of factors impacting disease-free survival

<table>
<thead>
<tr>
<th>Variable</th>
<th>Categorization</th>
<th>N</th>
<th>No. of events</th>
<th>P</th>
<th>HR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER</td>
<td>Positive</td>
<td>230</td>
<td>73</td>
<td>&lt;0.0001</td>
<td>0.391 (0.268–0.570)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>77</td>
<td>44</td>
<td>&lt;0.0001</td>
<td>0.513 (0.354–0.743)</td>
</tr>
<tr>
<td>PR</td>
<td>Positive</td>
<td>206</td>
<td>66</td>
<td>&lt;0.0001</td>
<td>2.682 (1.701–4.230)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>99</td>
<td>50</td>
<td>&lt;0.0001</td>
<td>2.654 (1.777–3.965)</td>
</tr>
<tr>
<td>HER2</td>
<td>Positive</td>
<td>46</td>
<td>28</td>
<td>&lt;0.0001</td>
<td>1.744 (1.193–2.548)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>187</td>
<td>58</td>
<td>0.0036</td>
<td>1.714 (1.088–2.701)</td>
</tr>
<tr>
<td>Nodal Status</td>
<td>Positive</td>
<td>110</td>
<td>55</td>
<td>0.0036</td>
<td>1.744 (1.193–2.548)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>179</td>
<td>44</td>
<td>0.0188</td>
<td>1.714 (1.088–2.701)</td>
</tr>
<tr>
<td>Grade</td>
<td>G3</td>
<td>138</td>
<td>60</td>
<td>0.0036</td>
<td>1.744 (1.193–2.548)</td>
</tr>
<tr>
<td></td>
<td>G1 and G2</td>
<td>158</td>
<td>49</td>
<td>0.0188</td>
<td>1.714 (1.088–2.701)</td>
</tr>
<tr>
<td>Gli1 (epithelial)</td>
<td>Positive</td>
<td>200</td>
<td>83</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>89</td>
<td>24</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
compound that is approved for the management of metastatic or locally advanced basal cell carcinomas and being explored in other cancers (http://clinicaltrials.gov). Our work indicates that patients who developed resistance to tamoxifen, GDC-0049 alone will be effective in treating recurrent tumors and therefore designing appropriate clinical trials is warranted. It will be interesting to determine if resistance to other endocrine therapies such as aromatase inhibitors results in Hh pathway activation, which we plan to pursue in the future.

One of the major challenges in treating a drug-resistant tumor is the complex networking pathways that are involved in the cross-talk between the distinct signaling pathways. The PI3K/AKT pathway is one of many pathways that contribute to endocrine resistance (37). Activation of the PI3K/AKT and the p12/44 mitogen-activated protein kinase pathways by receptors such as EGFR and IGF1-R suppresses the expression of ER and PR (29, 38–42) and therefore, reduce estrogen dependence. Our work clearly shows cross-talk between PI3K/AKT and Hh pathway, and provides an additional mechanism for PI3K/AKT-mediated endocrine resistance. Importantly, we showed that increased activity of PI3K/AKT activity could stabilize SMO and Gli1 protein by suppressing GSK3β-mediated phosphorylation and proteasomal degradation, leading to noncanonical Hh pathway activation. Although a previous study reported cross-talk between PI3K/AKT and Hh pathway, it is currently being pursued. Further, our finding underscores the importance of PI3K pathway in activating Hh pathway and provides the rationale for combinatorial targeted therapy in breast cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: B. Ramaswamy, S. Majumder
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Ramaswamy, Y. Lu, K. Teng, G. J. Nuovo, C. L. Shapiro
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Ramaswamy, Y. Lu, K. Teng, G. J. Nuovo, X. Li, S. Majumder
Writing, review, and/or revision of the manuscript: B. Ramaswamy, Y. Lu, X. Li, C. L. Shapiro, S. Majumder
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Teng, S. Majumder
Study supervision: B. Ramaswamy, S. Majumder

Acknowledgments
We thank Dr. Michael Ostrowski for critical reading of the manuscript and editorial suggestions and Drs. Samson T. Jacob, Miguel A. Villalona, Gustavo Leone, Guido Marrucci, and Cynthia Timmers for critically reading the manuscript. We thank Dr. Hiroshi Sasaki for kindly providing the Gli BS-5-Luc plasmid and Dr. Kristian Helin for providing the PI3K and AKT expression vectors. We also thank Sathavisha Roy and Thomas Kaffenberger for technical help.

Grant Support
This work was supported by National Institutes of Health Grant CA137567 to S. Majumder, CA133250-01 to B. Ramaswamy, Pelotonia Idea grant to S. Majumder and B. Ramaswamy, and Experimental Therapeutics OSU internal grant to S. Majumder and B. Ramaswamy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 2, 2012; revised May 30, 2012; accepted July 16, 2012; published OnlineFirst August 8, 2012.

References

Table 3. Univariate survival analysis results for overall survival

<table>
<thead>
<tr>
<th>Variable</th>
<th>Categorization</th>
<th>N</th>
<th>No. of events</th>
<th>P</th>
<th>HR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER</td>
<td>Positive</td>
<td>230</td>
<td>65</td>
<td>&lt;0.0001</td>
<td>0.428 (0.286–0.640)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>77</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>Positive</td>
<td>206</td>
<td>58</td>
<td>0.0013</td>
<td>0.526 (0.355–0.778)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>99</td>
<td>45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HER2</td>
<td>Positive</td>
<td>46</td>
<td>26</td>
<td>0.0001</td>
<td>2.564 (1.592–4.129)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>187</td>
<td>51</td>
<td>&lt;0.0001</td>
<td>2.983 (1.928–4.616)</td>
</tr>
<tr>
<td>Nodal Status</td>
<td>Positive</td>
<td>110</td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>179</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td>G3</td>
<td>138</td>
<td>40</td>
<td>0.002</td>
<td>1.907 (1.266–2.872)</td>
</tr>
<tr>
<td></td>
<td>G1 and G2</td>
<td>158</td>
<td>55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gli1 (epithelial)</td>
<td>Positive</td>
<td>200</td>
<td>74</td>
<td>0.0055</td>
<td>2.076 (1.240–3.476)</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>89</td>
<td>18</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway

Bhuvaneswari Ramaswamy, Yuanzhi Lu, Kun-yu Teng, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-1248

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/08/09/0008-5472.CAN-12-1248.DC1

Cited articles
This article cites 42 articles, 27 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/19/5048.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/72/19/5048.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.